Bardoxolone (CDDO, RTA 401) methyl is an orally active and brain-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC50 value of 0.29 µM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFkappaB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD)[1][2][3][4][5].
Molecular Weight:
505.69
Purity:
99.66
CAS Number:
[218600-53-4]
Formula:
C32H43NO4
Target:
Keap1-Nrf2,SARS-CoV,Virus Protease
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted